查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2021500

神经回馈平台市场预测至2034年－全球分析（按组件、模式、平台类型、年龄层、应用、最终用户和地区划分）

Neurofeedback Platforms Market Forecasts to 2034 - Global Analysis By Component (Hardware, Software and Services), Modality, Platform Type, Age Group, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球神经反馈平台市场规模将达到 13 亿美元，并在预测期内以 12.7% 的复合年增长率增长，到 2034 年将达到 34 亿美元。

神经回馈平台是指一种整合了临床和消费应用功能的系统，它透过脑电图（EEG）、功能性磁振造影（fMRI）、脑血流图或延迟皮质电位记录等技术即时测量大脑的电活动，并提供即时的听觉、视觉或触觉回馈讯号，以训练使用者调节自我调节与注意力、放鬆、认知功能和神经系统症状管理模式的特定神经系统症状管理。这些平台包括配备电极的头戴式耳机、讯号放大硬体、即时讯号处理软体、游戏化训练介面、会话管理入口网站以及进度追踪和分析功能，并被用于治疗注意力不足过动症（ADHD）、焦虑症管理、巅峰表现训练和创伤后压力症候群（PTSD）。

对过动症和心理健康治疗的需求

对注意力不足过动症 (ADHD) 和心理健康治疗日益增长的需求是推动神经回馈平台广泛应用的主要动力。这是因为临床医生和患者都在寻求非药物、无副作用的干预措施来治疗注意力不足过动症、焦虑症和忧郁症，尤其是对于那些对药物治疗无效的患者群体。美国食品药物管理局 (FDA)核准基于神经反馈的 ADHD 疗法，确立了其监管合法性，扩大了保险覆盖范围，并提高了医生转诊的可信度。越来越多的家长倾向于为儿童患者选择非兴奋剂类 ADHD 干预措施，这推动了消费者对经认证的临床神经反馈计画的需求，从而导致临床心理学和儿童神经病学领域对神经反馈平台的持续增长。

临床证据与保险报销之间的差距。

临床证据品质的差异以及保险报销范围的限制是神经回馈技术推广应用的主要障碍。这是因为，由于缺乏卫生技术评估机构核准保险覆盖所需的循证随机对照试验，神经反馈平台提供者难以获得保险公司的报销。临床研究中神经回馈方案、电极放置标准和结果测量方法的异质性限制了透过荟萃分析整合证据以加强报销的努力。在无保险市场中，高昂的自费治疗费用造成了就医障碍，限制了神经回馈技术的普及，使其仅限于高所得患者群体，并限制了潜在市场（TAM）在专业私人医疗保健环境之外的发展。

提供远端和居家神经回馈

将价格亲民的消费级脑电图（EEG）头戴设备与远端医疗平台结合，可以实现居家监督训练项目，从而消除地域限制，减轻服务不足或行动不便地区患者的就诊负担。因此，远端和居家神经回馈疗法的提供为大幅扩大服务覆盖范围提供了重要机会。德国、日本和美国正在不断完善的数位疗法法规结构，为透过认证平台订阅提供的处方笺位神经回馈计画创建了报销途径。与诊所治疗方案相比，居家训练的单次治疗成本大幅降低，其经济效益显着，正在扩大能够从大规模、持续性神经反馈干预中获益的患者群体。

相互竞争的数位治疗方法

来自FDA已通过核准的数位疗法应用程式的竞争日益激烈，这些应用程式透过认知行为疗法、生物回馈疗法和游戏化等行为干预手段，治疗注意力不足过动症（ADHD）、焦虑症和忧郁症，对神经反馈疗法构成商业性威胁。这是因为拥有更强临床证据的竞争平台可能会在保险报销和医生推荐方面获得优先权，从而挤占神经反馈疗法的市场份额。数位疗法与製药公司的合作，透过提供药物和数位支援项目相结合的套餐，加剧了保险报销管道的竞争。如果没有类似的商业基础设施，独立的神经回馈平台营运商将难以与之竞争。此外，面向消费者的冥想和正念应用程式也在争夺消费者的时间和预算，这与面向消费者的神经反馈订阅服务类似。

新冠疫情的影响：

新冠疫情引发了一场严重的心理健康危机，大大提高了公众对注意力不足过动症（ADHD）、焦虑症和压力相关障碍（神经反馈平台的目标疾病）的认知度和治疗需求，并催生了远超疫情初期阶段的持续需求增长。疫情期间远端医疗监管的放宽使得远距神经回馈疗程得以开展，并加深了临床医生和患者对数位心理健康干预方法的理解。疫情后对心理健康技术平台的投资，持续为神经反馈平台的开发和商业化项目提供资金支持，这些项目在疫情期间就已吸引了数位健康投资者的关注。

在预测期内，服务业预计将占据最大份额。

在预测期内，服务板块预计将占据最大的市场份额。这是因为基于订阅的临床疗程交付模式能够产生持续性收入，其价值远超成熟神经回馈诊所一次性购买硬体的成本。透过託管服务合约提供全面疗程管理、临床医生培训和认证、方案库访问以及患者进展分析的平台提供商，相比仅提供硬体的收费，能够获得更高的客户维繫率和帐户终身收入。远距治疗服务的扩展增加了每个平台计费的神经回馈疗程数量，从而加速了业务收益的成长，使其高于硬体和软体板块。

在预测期内，脑电图神经回馈领域预计将呈现最高的复合年增长率。

在预测期内，脑电图（EEG）神经反馈领域预计将呈现最高的增长率，这主要得益于消费级EEG头戴设备成本的快速下降，从而扩大了临床和家庭市场；临床方案标准化方面的进展提高了治疗效果的一致性；以及在主要市场，医保报销范围扩大，将EEG神经反馈作为多动症和焦虑症的适应症。无线干电极EEG系统无需涂抹凝胶，显着提高了患者的接受度和治疗依从性，从而增强了医保报销谈判中临床疗效的证据。此外，智慧型手机连接的EEG系统支援患者在诊疗间隙进行居家持续训练，这为传统的按诊疗次数收费模式之外开闢了新的订阅收入来源。

市占率最大的地区：

在整个预测期内，北美预计将保持最大的市场份额。这主要归功于美国较高的注意力不足过动症（ADHD）诊断率和治疗率，从而产生了巨大的临床需求；ADHD治疗中神经反馈疗法的保险覆盖范围不断扩大；以及北美拥有成熟的临床神经反馈从业者群体，他们积极采用数位化平台工具。总部位于美国的神经回馈平台公司，例如Br​​ainMaster Technologies和BrainTrain Inc.，都拥有稳定的临床基本客群。美国强大的心理健康技术投资生态系统和完善的数位医疗报销体系，正在为北美的平台创新和商业性领先地位提供支援。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率。这主要归功于以往服务不足人口对注意力不足过动症（ADHD）和心理健康治疗方法的认知度迅速提高，医疗基础设施的扩展使得神经回馈临床服务得以开展，以及中国、日本、澳洲和韩国政府在心理健康领域的投资计画。随着亚太地区精神科评估基础设施的完善，ADHD的诊断率不断上升，从而推动了对临床平台采购的需求。中国和韩国本土神经回馈平台开发商生态系统的兴起，正在提升该地区市场的接受度。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章：执行摘要

第二章：引言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 促进因素
  • 抑制因子
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章：波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的竞争

第五章 全球神经回馈平台市场：按组件划分

  • 硬体
    • 电极类型
  • 软体
  • 服务

第六章 全球神经回馈平台市场：按模式划分

  • 脑电图神经回馈
  • 功能性磁振造影神经回馈
  • HEG神经回馈
  • SCP神经回馈

第七章 全球神经回馈平台市场：依平台类型划分

  • 独立系统
  • 基于云端的平台

第八章 全球神经回馈平台市场：依年龄组别划分

  • 儿童
  • 成人
  • 老年人

第九章 全球神经回馈平台市场：按应用划分

  • 过动症治疗
  • 焦虑和忧郁症的管理
  • 睡眠障碍
  • 认知功能改善
  • 疼痛管理
  • 其他用途

第十章 全球神经回馈平台市场：依最终用户划分

  • 医院和诊所
  • 健康中心
  • 研究机构
  • 普通家庭用户
  • 其他最终用户

第十一章 全球神经回馈平台市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十二章 主要发展

  • 合约、伙伴关係、合作关係、合资企业
  • 收购与併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十三章：公司简介

  • BrainMaster Technologies
  • Thought Technology Ltd.
  • NeuroCare Group
  • Mitsar Co. Ltd.
  • EEGer
  • BrainTrain Inc.
  • Neurofield Inc.
  • Zengar Institute
  • Cygnet Software
  • Neurobit Systems
  • Emotiv Inc.
  • OpenBCI
  • Natus Medical
  • Compumedics Neuroscan
  • Advanced Brain Monitoring
  • ANT Neuro
  • NeuroSky
  • BrainCo
Product Code: SMRC34840

According to Stratistics MRC, the Global Neurofeedback Platforms Market is accounted for $1.3 billion in 2026 and is expected to reach $3.4 billion by 2034 growing at a CAGR of 12.7% during the forecast period. Neurofeedback platforms refer to integrated clinical and consumer systems that measure real-time brain electrical activity through EEG, functional magnetic resonance imaging, hemoencephalography, or slow cortical potential recording, and provide immediate auditory, visual, or haptic feedback signals that train users to self-regulate specific neural oscillation patterns associated with attention, relaxation, cognitive performance, and neurological symptom management. These platforms encompass electrode headsets, signal amplification hardware, real-time signal processing software, gamified training interfaces, session management portals, and progress tracking analytics serving ADHD treatment, anxiety management, peak performance training, and post-traumatic stress disorder therapies.

Market Dynamics:

Driver:

ADHD and Mental Health Treatment Demand

Escalating ADHD and mental health treatment demand is the primary driver expanding neurofeedback platform adoption as clinicians and patients seek non-pharmacological, side-effect-free interventions for attention deficit disorders, anxiety, and depression that medication-resistant patient populations particularly require. FDA clearance of neurofeedback-based ADHD treatments has established regulatory legitimacy that is expanding insurance reimbursement coverage and physician referral confidence. Growing parental preference for non-stimulant ADHD interventions for pediatric patients is generating strong consumer demand for certified clinical neurofeedback programs that creates sustained platform procurement growth across clinical psychology and pediatric neurology practice settings.

Restraint:

Clinical Evidence and Reimbursement Gaps

Inconsistent clinical evidence quality and limited insurance reimbursement coverage represent significant adoption barriers as neurofeedback platform operators struggle to secure payer coverage without the randomized controlled trial evidence bases that health technology assessment bodies require for positive coverage determinations. Heterogeneity of neurofeedback protocols, electrode placement standards, and outcome measurement approaches across clinical studies limits meta-analytic evidence synthesis that would strengthen reimbursement advocacy. High out-of-pocket session costs in markets without coverage create access barriers that confine neurofeedback adoption to higher-income patient segments and constrain total addressable market development beyond specialty private pay clinical settings.

Opportunity:

Remote and Home-Based Neurofeedback Delivery

Remote and home-based neurofeedback delivery represents a transformational access expansion opportunity as affordable consumer-grade EEG headsets and telehealth platform integration enable supervised at-home training programs that eliminate geographic access barriers and session attendance burden for patients in underserved rural or mobility-constrained populations. Digital therapeutics regulatory frameworks emerging in Germany, Japan, and the United States are creating reimbursement pathways for prescription digital neurofeedback programs delivered through certified platform subscriptions. Home training economics with dramatically reduced per-session cost compared to clinic-based protocols are expanding the viable patient population for sustained neurofeedback intervention at scale.

Threat:

Competing Digital Therapeutics Modalities

Competition from FDA-cleared digital therapeutic applications addressing ADHD, anxiety, and depression through cognitive behavioral therapy, biofeedback, and gamified behavioral intervention modalities represents a growing commercial threat as competing platforms with stronger clinical evidence bases may preferentially capture reimbursement coverage and physician recommendation at the expense of neurofeedback alternatives. Pharmaceutical company digital therapy partnerships creating bundled medication and digital support programs are generating competing reimbursement-supported access pathways that independent neurofeedback platform operators cannot match without equivalent commercial infrastructure. Direct-to-consumer meditation and mindfulness apps capturing discretionary mental wellness spending are competing for the same consumer time and budget allocation as consumer neurofeedback subscriptions.

Covid-19 Impact:

COVID-19 generated a significant mental health crisis that substantially expanded public awareness and treatment-seeking behavior for ADHD, anxiety, and stress-related conditions that neurofeedback platforms address, creating demand growth that persisted well beyond initial pandemic phases. Telehealth regulatory liberalizations during the pandemic period enabled remote neurofeedback session delivery that expanded clinician and patient familiarity with digital mental health intervention modalities. Post-pandemic investment in mental health technology platforms has sustained capital availability for neurofeedback platform development and commercialization programs that benefited from pandemic-era digital health investor attention.

The services segment is expected to be the largest during the forecast period

The services segment is expected to account for the largest market share during the forecast period, due to the subscription-based clinical session delivery model generating recurring revenue that substantially exceeds one-time hardware procurement values in established neurofeedback practice accounts. Platform operators providing comprehensive session management, clinician training certification, protocol library access, and patient progress analytics through managed service arrangements are achieving superior customer retention and lifetime account revenue versus hardware-only vendor relationships. Teletherapy delivery expansion is increasing the volume of billable neurofeedback sessions per platform installation, amplifying services revenue growth relative to hardware and software segments.

The EEG neurofeedback segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the EEG neurofeedback segment is predicted to witness the highest growth rate, driven by rapidly declining consumer EEG headset costs that are expanding the addressable clinical and home-use market, growing clinical protocol standardization improving treatment outcome consistency, and expanding insurance reimbursement coverage in major markets recognizing EEG neurofeedback for ADHD and anxiety indications. Wireless dry-electrode EEG systems eliminating gel preparation burden are significantly improving patient acceptance and session compliance rates that improve clinical outcome evidence for reimbursement negotiations. Smartphone-connected EEG systems enabling continuous home training between clinic sessions are generating new subscription revenue streams beyond traditional office-based session billing models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the high ADHD diagnosis and treatment rate in the United States generating large clinical demand, growing insurance plan coverage for neurofeedback ADHD treatment, and established clinical neurofeedback practitioner community adopting digital platform tools. U.S.-based neurofeedback platform companies including BrainMaster Technologies and BrainTrain Inc. maintain established clinical customer bases. Strong mental health technology investment ecosystem and digital health reimbursement framework development in the United States sustains North American platform innovation and commercial leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly growing awareness of ADHD and mental health treatment options across previously underserved populations, expanding healthcare infrastructure enabling neurofeedback clinical service delivery, and government mental health investment programs in China, Japan, Australia, and South Korea. Rising ADHD diagnosis rates as psychiatric assessment infrastructure develops across Asia Pacific markets are generating growing clinical platform procurement demand. Domestic neurofeedback platform developer ecosystem emergence in China and South Korea is building regional market capacity.

Key players in the market

Some of the key players in Neurofeedback Platforms Market include BrainMaster Technologies, Thought Technology Ltd., NeuroCare Group, Mitsar Co. Ltd., EEGer, BrainTrain Inc., Neurofield Inc., Zengar Institute, Cygnet Software, Neurobit Systems, Emotiv Inc., OpenBCI, Natus Medical, Compumedics Neuroscan, Advanced Brain Monitoring, ANT Neuro, NeuroSky, and BrainCo.

Key Developments:

In March 2026, OpenBCI introduced the Galea Gen 2 multimodal biosensing headset combining EEG, EMG, and eye tracking for combined neurofeedback and biofeedback research and clinical training protocols.

In February 2026, Thought Technology Ltd. released the ProComp Infiniti 8 multichannel biofeedback and neurofeedback system with enhanced wireless EEG acquisition and integrated teletherapy session delivery capabilities.

In December 2025, NeuroCare Group launched its cloud-based neurofeedback protocol management platform integrating AI-driven session personalization and remote therapist supervision for multi-site clinical network deployment.

Components Covered:

  • Hardware
  • Software
  • Services

Modalities Covered:

  • EEG Neurofeedback
  • fMRI Neurofeedback
  • HEG Neurofeedback
  • SCP Neurofeedback

Platform Types Covered:

  • Standalone Systems
  • Cloud-Based Platforms

Age Groups Covered:

  • Pediatric
  • Adults
  • Geriatric

Applications Covered:

  • ADHD Treatment
  • Anxiety & Depression Management
  • Sleep Disorders
  • Cognitive Enhancement
  • Pain Management
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Wellness Centers
  • Research Institutions
  • Home Users
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurofeedback Platforms Market, By Component

  • 5.1 Hardware
    • 5.1.1 Electrode Type
  • 5.2 Software
  • 5.3 Services

6 Global Neurofeedback Platforms Market, By Modality

  • 6.1 EEG Neurofeedback
  • 6.2 fMRI Neurofeedback
  • 6.3 HEG Neurofeedback
  • 6.4 SCP Neurofeedback

7 Global Neurofeedback Platforms Market, By Platform Type

  • 7.1 Standalone Systems
  • 7.2 Cloud-Based Platforms

8 Global Neurofeedback Platforms Market, By Age Group

  • 8.1 Pediatric
  • 8.2 Adults
  • 8.3 Geriatric

9 Global Neurofeedback Platforms Market, By Application

  • 9.1 ADHD Treatment
  • 9.2 Anxiety & Depression Management
  • 9.3 Sleep Disorders
  • 9.4 Cognitive Enhancement
  • 9.5 Pain Management
  • 9.6 Other Applications

10 Global Neurofeedback Platforms Market, By End User

  • 10.1 Hospitals & Clinics
  • 10.2 Wellness Centers
  • 10.3 Research Institutions
  • 10.4 Home Users
  • 10.5 Other End Users

11 Global Neurofeedback Platforms Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 BrainMaster Technologies
  • 13.2 Thought Technology Ltd.
  • 13.3 NeuroCare Group
  • 13.4 Mitsar Co. Ltd.
  • 13.5 EEGer
  • 13.6 BrainTrain Inc.
  • 13.7 Neurofield Inc.
  • 13.8 Zengar Institute
  • 13.9 Cygnet Software
  • 13.10 Neurobit Systems
  • 13.11 Emotiv Inc.
  • 13.12 OpenBCI
  • 13.13 Natus Medical
  • 13.14 Compumedics Neuroscan
  • 13.15 Advanced Brain Monitoring
  • 13.16 ANT Neuro
  • 13.17 NeuroSky
  • 13.18 BrainCo

List of Tables

  • Table 1 Global Neurofeedback Platforms Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neurofeedback Platforms Market Outlook, By Component (2023-2034) ($MN)
  • Table 3 Global Neurofeedback Platforms Market Outlook, By Hardware (2023-2034) ($MN)
  • Table 4 Global Neurofeedback Platforms Market Outlook, By Electrode Type (2023-2034) ($MN)
  • Table 5 Global Neurofeedback Platforms Market Outlook, By Software (2023-2034) ($MN)
  • Table 6 Global Neurofeedback Platforms Market Outlook, By Services (2023-2034) ($MN)
  • Table 7 Global Neurofeedback Platforms Market Outlook, By Modality (2023-2034) ($MN)
  • Table 8 Global Neurofeedback Platforms Market Outlook, By EEG Neurofeedback (2023-2034) ($MN)
  • Table 9 Global Neurofeedback Platforms Market Outlook, By fMRI Neurofeedback (2023-2034) ($MN)
  • Table 10 Global Neurofeedback Platforms Market Outlook, By HEG Neurofeedback (2023-2034) ($MN)
  • Table 11 Global Neurofeedback Platforms Market Outlook, By SCP Neurofeedback (2023-2034) ($MN)
  • Table 12 Global Neurofeedback Platforms Market Outlook, By Platform Type (2023-2034) ($MN)
  • Table 13 Global Neurofeedback Platforms Market Outlook, By Standalone Systems (2023-2034) ($MN)
  • Table 14 Global Neurofeedback Platforms Market Outlook, By Cloud-Based Platforms (2023-2034) ($MN)
  • Table 15 Global Neurofeedback Platforms Market Outlook, By Age Group (2023-2034) ($MN)
  • Table 16 Global Neurofeedback Platforms Market Outlook, By Pediatric (2023-2034) ($MN)
  • Table 17 Global Neurofeedback Platforms Market Outlook, By Adults (2023-2034) ($MN)
  • Table 18 Global Neurofeedback Platforms Market Outlook, By Geriatric (2023-2034) ($MN)
  • Table 19 Global Neurofeedback Platforms Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Neurofeedback Platforms Market Outlook, By ADHD Treatment (2023-2034) ($MN)
  • Table 21 Global Neurofeedback Platforms Market Outlook, By Anxiety & Depression Management (2023-2034) ($MN)
  • Table 22 Global Neurofeedback Platforms Market Outlook, By Sleep Disorders (2023-2034) ($MN)
  • Table 23 Global Neurofeedback Platforms Market Outlook, By Cognitive Enhancement (2023-2034) ($MN)
  • Table 24 Global Neurofeedback Platforms Market Outlook, By Pain Management (2023-2034) ($MN)
  • Table 25 Global Neurofeedback Platforms Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 26 Global Neurofeedback Platforms Market Outlook, By End User (2023-2034) ($MN)
  • Table 27 Global Neurofeedback Platforms Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 28 Global Neurofeedback Platforms Market Outlook, By Wellness Centers (2023-2034) ($MN)
  • Table 29 Global Neurofeedback Platforms Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 30 Global Neurofeedback Platforms Market Outlook, By Home Users (2023-2034) ($MN)
  • Table 31 Global Neurofeedback Platforms Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.